Axim Signs Deal to Advance Clinical Trials of Cannabis-based MedChew Rx Gum to Treat MS Pain

Axim Biotechnologies recently announced that its U.K. partner, Quay Pharmaceuticals, has secured licenses from the British Home Office to continue developing and importing its medical cannabinoid product MedChew Rx — a potential treatment for pain and spasticity in people with multiple sclerosis (MS), among other illnesses.

MedChew Rx is a gum containing 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC). The gum is intended to offer patients more consistent relief than existing cannabis-derived products that are smoked or eaten.

To develop its CBD-based gums and conduct clinical trials, Axim collaborates with its partners to procure strains of cannabis from the Netherlands, and then extract and purify those strains into pharmaceutical-grade cannabinoids. A Dutch company, Bedrocan, produces these strains at a certified facility under the supervision of the Dutch government’s Office of Medicinal Cannabis.

Axim says several studies are underway at U.S. and European universities to evaluating the effects of its products. Last

... read more at: https://multiplesclerosisnewstoday.com/2017/05/03/ms-patients-benefit-axim-cannabis-based-medchew-rx-gum-therapy/

Leave a Reply

Your email address will not be published. Required fields are marked *